JAZZ ▼ -0.8% - Jazz Pharmaceuticals plc
$JAZZ JAZZ - Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
23-OCT-2026 10:15 AM ET
Share this post
More filings for $JAZZ
JAZZ ▲ +0.5% - Jazz Pharmaceuticals plcSep 15, 2026JAZZ ▲ +0.7% - Jazz Pharmaceuticals plcSep 2, 2026JAZZ ▲ +0.0% - Jazz Pharmaceuticals plcAug 31, 2026JAZZ - Jazz Pharmaceuticals plc - SEC Filing Update (06-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 6, 2026
View full $JAZZ filing history →💬 Comments
Loading comments…
Leave a comment